About Alzinova
Alzinova AB is a Swedish pharmaceutical enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.
Read more »Research
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers. It is currently under validation as a diagnostic tool.
News
-
Initiala resultat från förstudie med vaccin ALZ-101 bekräftar god säkerhetsprofil i icke-humana primater
Alzinova har idag erhållit delresultat från vaccinationsstudien på icke-humana primater (makakapor), förstudien till GLP-toxikologistudien, som… Read more »
-
Europeiska Kommissionen offentliggör Alzinovas Horizon 2020 steg 1 rapport
Alzinova erhöll i våras ett bidrag om €50,000 i syfte att utarbeta en kommersialiseringsplan för… Read more »
-
Alzinova inleder idag förstudie till den slutliga GLP-toxikologistudien på vaccin ALZ-101
Det pre-kliniska arbetet med vaccinet ALZ-101 fortskrider enligt plan. Idag inleds en vaccinationsstudie på icke-humana… Read more »